Physician profile
Walter A Ezeigbo
NPI 1306839659
$7,869.49
in general payments reported to CMS, 2019-2025
37 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $750 · 2021: $1,450 · 2022: $1,040 · 2023: $1,462 · 2024: $1,595 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,334.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,726.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,079.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.07 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $290.57 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $262.71 | 2019-2023 | |
| Glaxosmithkline, LLC. | $218.22 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $169.42 | 2019-2025 | |
| Amgen INC. | $158.45 | 2019-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $128.41 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.10 | 2020-2023 | Xifaxan, Trulance |
| Acadia Pharmaceuticals INC | $125.00 | 2024 | Nuplazid |
| Abbvie INC. | $124.12 | 2024 | |
| Antares Pharma, INC. | $113.92 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Halozyme INC | $105.43 | 2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $68.18 | 2021-2022 | |
| Eisai INC. | $54.89 | 2019 | |
| Verity Pharmaceuticals INC. | $41.17 | 2024 | Tlando |
| Tolmar, INC. | $35.14 | 2023-2025 | Jatenzo |
| Corcept Therapeutics | $33.87 | 2025 | Korlym |
| Acerus Pharmaceuticals Corporation | $31.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.08 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $29.98 | 2025 | Rexulti |
| Abbott Laboratories | $29.97 | 2023 | Proclaim |
| Biohaven Pharmaceuticals, INC. | $25.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.70 | 2024 | |
| Tris Pharma INC | $18.74 | 2019 | |
| Sanofi Pasteur INC. | $17.83 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.15 | 2022 | |
| Exact Sciences Corporation | $16.07 | 2025 | The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $14.89 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.50 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.98 | 2023 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $12.99 | 2022 | |
| Currax Pharmaceuticals LLC | $11.67 | 2019 | |
| Neos Therapeutics, LP | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Ezeigbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.